Hikal Limited
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are…
What Hikal files
- Others53
- Important34
- Investor Meet28
- Updates16
- Board Meeting12
- Dividend/Bonus8
Here's a concise, retail-friendly summary: **1. Business Performance:** Hikal roared back in Q3 FY26! Consolidated revenue jumped to ₹494 Cr, a 55% QoQ surge, with EBITDA at ₹83 Cr. The Pharma segment revenue hit ₹337 Cr, leading the recovery as regulatory issues are mostly addressed and supplies resume. Crop Protection...
Hikal's Q2 revenue was ₹319 Cr (down 29% YoY) with a PAT of (₹35) Cr. For H1, revenue stood at ₹699 Cr (down 19% YoY) with a PAT of (₹57) Cr. Performance was impacted by deferments in the Pharmaceutical business following a US FDA warning letter, and muted demand in...
Here's a concise summary for Hikal Ltd.: **1. Business Performance:** Hikal's Q1 FY26 saw consolidated revenue at Rs. 380 Cr and EBITDA at Rs. 25 Cr, a slower-than-expected start. The Pharma segment generated Rs. 203 Cr, with EBIT at -12.9%, impacted by temporary hold on off-take following a US FDA...
Here is the summary for Hikal Ltd.'s financial update: **1. Financial Highlights:** Hikal's Q1 FY26 consolidated revenue hit Rs. 380 Cr, with EBITDA at Rs. 25 Cr (6.5% margin), and a net loss of Rs. 23 Cr. Pharma revenue (Rs. 203 Cr) saw an EBIT loss due to temporary off-take...
1. Financial Highlights: Hikal Ltd reported FY25 revenue of Rs 1,860 Cr, up 4% YoY, with EBITDA increasing 23% to Rs 328 Cr, driving margin expansion by 270 bps to 17.7%. Q4 revenue jumped 23% QoQ to Rs 552 Cr, with EBITDA margin rising to 22.4%. Net profit rose 31%...